Market Research Logo

Sedation - Pipeline Review, H1 2015

Sedation - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Sedation - Pipeline Review, H1 2015’, provides an overview of the Sedation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sedation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sedation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sedation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sedation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Sedation Overview
Therapeutics Development
Pipeline Products for Sedation - Overview
Pipeline Products for Sedation - Comparative Analysis
Sedation - Therapeutics under Development by Companies
Sedation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Sedation - Products under Development by Companies
Sedation - Companies Involved in Therapeutics Development
Advicenne Pharma
AstraZeneca PLC
Maruishi Pharmaceutical Co., Ltd.
NanoMedex Pharmaceuticals, Inc.
Paion AG
Sedation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABP-700 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADV-6209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clonidine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MR-04A3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol Microemulsion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sedation - Recent Pipeline Updates
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News & Press Releases
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
Oct 10, 2014: Paion Expects Ono’S Remimazolm Decision On Filing In Japan In November 2014
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials
Nov 23, 2013: PAION announces positive End-of-Phase II Meeting with FDA for Remimazolam in procedural sedation
Aug 05, 2013: GERMAN REGULATORY AUTHORITY APPROVED PHASE II STUDY OF REMIMAZOLAM IN INDICATION ANAESTHESIA
Aug 01, 2013: PAION'S PARTNER ONO STOPPED ITS DOSE FINDING, EXPLORATIVE PHASE II TRIAL IN ICU SEDATION WITH REMIMAZOLAM AND PLANS TO ADAPT THE DOSE REGIME FOR A NEW STUDY
May 08, 2013: Paion's Partner Ono Pharma Completes Recruitment For Phase II/III Study Of Remimazolam For General Anesthesia
Dec 18, 2012: Paion Receives $3m Milestone Payment From Ono Pharma Following Enrollment Of First Patient In Phase II/III Study Of Remimazolam
Nov 05, 2012: Paion's Partner Ono Pharma Intiates Phase II/III Study With Short-acting Anaesthetic/Sedative Remimazolam In Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sedation, H1 2015
Number of Products under Development for Sedation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Sedation - Pipeline by Advicenne Pharma, H1 2015
Sedation - Pipeline by AstraZeneca PLC, H1 2015
Sedation - Pipeline by Maruishi Pharmaceutical Co., Ltd., H1 2015
Sedation - Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2015
Sedation - Pipeline by Paion AG, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Sedation Therapeutics - Recent Pipeline Updates, H1 2015
Sedation - Dormant Projects, H1 2015
Sedation - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Sedation, H1 2015
Number of Products under Development for Sedation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report